TCGA-BA-5559-01A-01R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.475570776
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.390
- E2F_TARGETS+0.280
- MYOGENESIS+0.260
- G2M_CHECKPOINT+0.240
- INTERFERON_GAMMA_RESPONSE+0.170
- IL6_JAK_STAT3_SIGNALING+0.160
- MITOTIC_SPINDLE+0.160
- SPERMATOGENESIS+0.150
- KRAS_SIGNALING_DN+0.040
- WNT_BETA_CATENIN_SIGNALING+0.010
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- MYC_TARGETS_V1-0.490
- OXIDATIVE_PHOSPHORYLATION-0.470
- MTORC1_SIGNALING-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.460
- CHOLESTEROL_HOMEOSTASIS-0.440
- GLYCOLYSIS-0.430
- HYPOXIA-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.885 |
| 2 | DRR168597 | — | — | 0.868 |
| 3 | SRR602753 | GTEX | — | 0.845 |
| 4 | SRR2932833 | — | — | 0.834 |
| 5 | SRR598533 | GTEX | — | 0.833 |
| 6 | MNG83 | — | — | 0.830 |
| 7 | SRR5088892 | — | — | 0.829 |
| 8 | X65f5effa.07f7.4ed3.9e0a.3a0d9d451474 | — | cohortA1 | 0.821 |
| 9 | TCGA-QK-A6IF-01A-11R-A31N-07 | — | — | 0.816 |
| 10 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |